Liposomal Clodronate as a Therapy for Autoimmune Hemolytic Anemia
- Technology Benefits
- The method is less invasive than surgery (splenectomy)Decrease use of steroidsDecrease side effects
- Technology Application
- Therapy for autoimmune hemolytic anemiaThe therapy is applicable to both humans and companion animals
- Detailed Technology Description
- The efficacy of this therapy has been demonstrated by some strong in vivo data obtained in mice and dogs with AIHA.Using a mouse model in which animals were given anti red blood cell antibodies, treatment with liposomal clodronate substantially decreased red blood cell destruction.In addition, this effect was detected within hours and lasted at least a week.RBC clearance and the effects of LC treatment in dogs with AIHA. RBC clearance in 6 dogs with spontaneous AIHA was assessed by flow cytometry prior to treatment and again 24 hours after treatment with LC and the mean (┬▒ SE) percentage of labeled RBC present in circulation at each time point post infusion was determined. (B) RBC clearance kinetics were determined again 24 hours after treatment with 0.5 mL/kg LC. In 4 dogs (Nonresponders), there was no change in RBC clearance compared to clearance prior to treatment with LC, whereas in 2 dogs (Responders), RBC clearance was markedly reduced.
- *Abstract
-
This invention is using liposomal clodronate as a therapy for autoimmune hemolytic anemia (AIHA).
- *Principal Investigator
-
Name: John Kappler, Professor
Department: Integrated Department of Immunology
Name: Philippa Marrack, Professor
Department: Integrated Department of Immunology
- Country/Region
- USA
For more information, please click Here
